nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) play pivotal roles in the development of the nervous system (101).
Physical activity seems to be a key intervention to trigger the processes through which neurotrophins
mediate energy metabolism and their neural plasticity.
Meanwhile, immunohistochemistry also showed that the expression levels of neurotrophins
were significantly reduced by fluorocitrate treatment (Figures 4(e) and 4(f)).
BDNF and NGF are the most abundant and widely distributed neurotrophins
in the brain.
and their receptors: roles in plasticity, neurodegeneration and neuroprotection," Biochemical Society Transactions, vol.
In our experiment, we observed that lithium prevented memory impairment and increased hippocampal BDNF, NGF, and GDNF neurotrophin
expression in experimental pneumococcal meningitis.
Schor, "p75 neurotrophin
receptor and fenretinide-induced signaling in neuroblastoma," Cancer Chemotherapy and Pharmacology, vol.
However, the underlying pharmacological mechanisms of ZZHPD on HPA axis, neurotrophin
levels and hippocampal neurogenesis remained to be ambiguous.
Furthermore, the expression patterns of NGF, NT-3, and NT-4/5 as well as neurotrophin
receptors suggest that the neurotrophin
system may also provide non-neuronal functions during tooth development (18).
secretory pathways and synaptic plasticity.
brain-derived neurotrophic factor (BDNF) and its tropomyosin-related kinase B receptor have been connected to the mechanism of action of antidepressants and the pathophysiology of major depressive disorder.[5,6] The neurotrophin
hypothesis of depression presumes that stress-induced reduction of BDNF signaling and neuronal plasticity causes atrophy and weakening of synaptic connections in specific brain areas, finally leading to altered information processing and mood disorders.[6,7] Furthermore, antidepressant treatment enhances BDNF signaling and, in the long term, increases BDNF-mediated neuronal plasticity in the brain, facilitating patient recovery.
Sarepta announced it has signed an agreement with Nationwide Children's Hospital giving Sarepta the exclusive option to a Nationwide Children's gene therapy candidate, neurotrophin
3, to treat Charcot-Marie-Tooth, or CMT, neuropathies, including CMT type 1A.